-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

3571 PB CD8 TN and CD4 TEM on day30 after Allo-HSCT Is a Predictive Marker for the Development of aGVHD

Program: Oral and Poster Abstracts
Session: 722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster II
Hematology Disease Topics & Pathways:
Research, Clinical Research, Study Population, Human
Sunday, December 10, 2023, 6:00 PM-8:00 PM

Takayuki Katagiri, MD, PhD1*, Tatuya Suwabe, MD, PhD2*, Kyoko Fuse3, Yasuhiko Shibasaki, MD, PhD4*, Jun Takizawa, MD, PhD5*, Hirohito Sone, MD, PhD4* and Masayoshi Masuko, MD, PhD3

1Department of Hematology, Niigata University Faculty of Medicine, NIIGATA-SHI CHUO-KU, NIG, Japan
2Niigata University Faculty of Medicine, NIIGATA-SHI CHUO-KU, Japan
3Department of Haematopoietic Cell Therapy, Niigata University Medical and Dental Hospital, Niigata, Japan
4Niigata University Faculty of Medicine, Niigata, Japan
5Department of Hematology, Endocrinology and Metabolism, Niigata University Faculty of Medicine, Niigata, Japan


Acute GVHD (aGVHD) is a common complication 20-60 days after allo-HSCT and can be life-threatening in some cases. It has been reported to be associated with T-cell immune reconstitution, but the detailed mechanisms are not clear. Early post-transplant lymphocyte recovery is mainly due to homeostatic peripheral expansion (HPE), which is variable depending on various factors such as donor source, recipient's age. T cell-related cytokines, such as sIL-2R , IL-7 and TNFr1 are known biomarkers for the aGVHD, but there are few reports that predict the aGVHD incidence rate using the peripheral blood (PB) lymphocyte subset. We evaluated the effect of PB lymphocyte subset in early post-transplant period on aGVHD.


We retrospectively analyzed 83 patients (40 in AML, 12 in ALL, 1 in MPAL, 13 in MDS, 2 in MPN, 9 in malignant lymphoma/LPD and 3 in AA) who underwent the allo-HSCT in our hospital from 2013 to 2023. The median age of patients was 44 years (range:17-66). Sixteen received BM, 47 received PB (including 28 with haploidentical (9 with ATG, 19 with PTCY)), and 20 received CB. GVHD prophylaxis was FK506+MTX in 61 patients, CyA+MTX in 3 and MMF+FK506+CY in 19. The median observation period was 495 [38-2983] days. PB lymphocyte subset (Naïve Tcell (TN):CD45RA+CD62L+, Central memory Tcell (TCM) :CD45RA-CD62L+, Effector memory Tcell (TEM) :CD45RA-CD62L-, Effector memory Tcell re-expressed CD45RA (TEMRA) :CD45RA+CD62L-, Th1:CD3+4+CXCR3+CCR6-, Th2:CD3+4+CXCR3-CCR6-, Th17:CD3+4+CXCR3-CCR6+) at day30 (range:28-35) after transplantation were analyzed by FCM.


Twenty-five patients had grade II-IV aGVHD, and 11 had grade Ⅲ-IV aGVHD. Patients with Grade II-IV aGVHD exhibited significantly lower proportion of CD8+TN as compared to non aGVHD groups (GVHD+: 17.7 ± 13.3%; GVHD-: 30.9 ± 16.3%; p < 0.001) . In contrast, the proportion of CD4+TEM and CD8+TEM were higher in the Grade II-IV acute GVHD group (GVHD+: 30.9 ± 23.1%; GVHD-: 21.9 ± 15.6%; p=0.04, GVHD+: 36.1 ± 16.2%; GVHD-: 22.7 ± 14.7%; p < 0.001, respectively). We found a strong statistical correlation between the proportion of CD8+TN and CD8+TEM. The cumulative incidences of Grade II-IV and III -IV acute GVHD at day + 100 for CD8+TN <20% group was 56.9% and 29.6% compared with 14.2% and 6.3% for the CD8+TN >20% group (p < 0.001 and p < 0.01). Similarly, the cumulative incidences of Grade II-IV and III -IV acute GVHD at day + 100 for CD4+TEM >30% group was 48.1% and 32.6% compared with 22.2% and 5.9% for the CD4+TEM <30% group (p= 0.02 and p < 0.01).

Two-year NRM was higher in the CD8+TN <20% group than in the CD8+TN >20% group (26.3% vs 4.2%, p=0.008). The two-year cumulative incidence of relapse (CIR) was comparable between the two groups, but tended to be lower in the mismatched CR group (CD8+TN <20%: 33.1% versus CD8+TN >20%: 43.4%, p=0.31).


PB CD8 TN and CD4 TEM fraction on day30 is a predictive biomarker for the development of acute GVHD.

Disclosures: No relevant conflicts of interest to declare.

*signifies non-member of ASH